Abir O. Kanaan, PharmD, RPh

Although evidence supports safety of apixaban and rivaroxaban relative to warfarin, researchers had not directly compared their bleeding risk until last year.

Inflammation fuels residual ASCVD risk; survey reveals hs-CRP testing gaps, persistent angina, and new therapies for cardiovascular health.

Pharmacists should consider GLP-1 receptor agonists as second-line agents in older adults with DKD when additional glycemic control is needed.